Our venture capital approach focuses on enabling founders to turn advanced science into viable, high-impact healthcare solutions. Avasa, for example is revolutionizing microsurgery with a coupler poised to become the new standard for reconnecting microvascular arteries. Nanophage is harnessing next generation bacteriophage technology to combat antibiotic-resistant infections.

Targeted MedTech VC investment, paired with our industry know-how is accelerating the journey from scientific breakthrough to scalable medical impact.